Medexus Pharma (MDP.T) is an arbitrage in the making

*originally published January 24, 2023

Medexus Pharmaceuticals (MDP.T) is a Canadian specialty pharma company servicing the North American market. The company has developed a robust portfolio of orphan drugs that continues to grow revenue, yet the stock market has completely missed the point.

Equity Guru founder, Chris Parry, dives into Medexus’ financials and discusses the disconnect between the company’s revenues and its market cap where Medexus is valued at one-quarter of the money it brings in the door. With new drugs continuing to join the company’s pipeline and ongoing growth of its existing drug offerings, there is a unique potential for investors.

Is it time to give Medexus consideration? Find out here.

Enjoy!

Health Science, Pharmaceuticals, Today's Analysis, Video

Related Posts

Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing

Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities

Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success

Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing

Medexus Pharmaceuticals (MDP.T) deals with its debentures

Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story

More on MDP.T

Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing

Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities

Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success

Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing

Medexus Pharmaceuticals (MDP.T) deals with its debentures

Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story